Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist

US11359027B2 · kind B2 · utility

Assignees

• Université Paris—Est Créteil Val de Marne · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• Sorbonne Universite · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Sebastien Maury · Paris, FR
• Jose Cohen · Jerusalem, IL
• Benoit Salomon · Villejuif, FR
• Sina Naserian · Saint-Maur-des-Fossés, FR
• Mathieu Leclerc · Paris, FR

Key dates

• Filing date: Jun 22, 2017
• Grant date: Jun 14, 2022
• Expiry date: Apr 18, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/998
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.